Isofol Medical AB (publ) Stock Nasdaq Stockholm
Equities
SE0009581051
Pharmaceuticals
Sales 2021 | 22.41M 2.07M | Sales 2022 | 12.8M 1.18M | Capitalization | 120M 11.02M |
---|---|---|---|---|---|
Net income 2021 | -200M -18.45M | Net income 2022 | -160M -14.76M | EV / Sales 2021 | 49.7 x |
Net cash position 2021 | 378M 34.84M | Net cash position 2022 | 187M 17.21M | EV / Sales 2022 | -5.24 x |
P/E ratio 2021 |
-5.8
x | P/E ratio 2022 |
-0.75
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 62.57% |
Managers | Title | Age | Since |
---|---|---|---|
Petter Lindqvist
CEO | Chief Executive Officer | 72 | Jan. 08 |
Magnus Hurst
DFI | Director of Finance/CFO | 68 | Jan. 09 |
Roger Tell
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lars Erik Lind
CHM | Chairman | 83 | - |
Sten Nilsson
BRD | Director/Board Member | 76 | Jan. 03 |
Alain Herrera
BRD | Director/Board Member | 74 | 17-12-31 |
1st Jan change | Capi. | |
---|---|---|
+7.91% | 72.81B | |
+12.64% | 9.13B | |
-10.56% | 5.13B | |
+58.79% | 4.99B | |
+4.07% | 3.9B | |
-16.90% | 2.48B | |
-26.13% | 2.32B | |
+19.31% | 2.17B | |
-0.50% | 1.64B |